Overview

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.
Takeda

Treatments:

Antibodies, Monoclonal
BB 1101
Daratumumab
Dexamethasone
Dexamethasone acetate
Glycine
Ixazomib